Question 1

What amounts of glutathione did the published studies use?

Accepted Answer

Five amounts appear in the human trials behind this page, all administered orally, once daily, and fixed from the first day to the last, which makes them study parameters rather than recommendations. The largest was in a 6-month randomized, double-blinded, placebo-controlled trial of oral GSH (250 or 1,000 mg/day), which ran two amounts side by side. A 3-week trial in obese men gave either 1000 mg GSH per day or placebo for 3 weeks. A six-month diabetes trial reports that 125 diabetic patients were additionally given 500 mg oral GSH supplementation daily for a period of six months, on top of their usual diabetes medicines. An acne trial gave 500 mg oral glutathione (n = 22) or placebo (n = 18) once daily for 4 weeks. The smallest amount appears within a combination: a vascular trial administered CIT+GSH (2 g + 200 mg: Setria®), meaning 2 g of the amino acid citrulline with 200 mg of a branded glutathione. The published range therefore extends from 200 mg to 1,000 mg daily, and the upper end was investigated for six months at most.

Question 2

Who received those amounts?

Accepted Answer

Mostly people with a specific condition, which matters because an amount chosen for a disease was never tested as a general-purpose figure. The one trial in a general population enrolled 54 non-smoking adults and measured stores in the body rather than any health outcome. The 1,000 mg three-week trial enrolled twenty subjects (10 patients with T2DM and 10 obese subjects), all of them men. The 500 mg six-month trial enrolled people already on diabetes treatment, aged between 30 and 78 years. The acne trial took people with mild to moderate acne, and the blood-vessel trial took healthy postmenopausal women. Children appear once. The GROW study was a phase II clinical trial in pancreatic insufficient patients with CF between the ages of 2 and 10 years, CF being cystic fibrosis, and its abstract does not state the amount given. Each figure on this page therefore comes attached to a population, and lifting one out of its trial removes the context that made it a reasonable choice for that group.

Question 3

How was glutathione given in the studies?

Accepted Answer

By mouth in every human trial with a stated amount, and by other routes everywhere else. The route changes what an amount means, so it belongs in the same sentence as any number. A 2025 narrative review covers the three routes people actually use for skin lightening, setting out to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. It reports no standard amount for any of them. Liposomal glutathione, a form wrapped in fat bubbles to protect it from digestion, appears as an animal treatment: in mice infected with tuberculosis, L-GSH supplementation increased total hepatic levels and reduced GSH, the liver being where it was measured. The remaining routes are specialised. Gerbils received glutathione mixed into their feed, and in one pharmacy experiment the oxidised form was added to intravenous feeding bags for premature newborns. A capsule, a cream, a drip and a feeding bag are four different exposures, and a milligram figure from one route does not describe a dose by any of the others.

Question 4

How often was glutathione given, and for how long?

Accepted Answer

Once a day in every human trial that states a schedule, and never longer than six months. No trial among the research behind this page split the daily amount into two doses or spaced doses further apart, so the once-daily pattern is a convention of these trials rather than a comparison that was tested. Durations clustered at two ends. The short trials ran three to four weeks, including the acne trial and the citrulline combination, which the registry lists as an Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function, now marked COMPLETED. The long trials ran six months, and in children the GROW trial gave reduced glutathione or placebo orally daily for 24 weeks. The longest trial also tells you something about timing within that window. In the six-month body-stores trial, GSH levels in blood increased after 1, 3 and 6 months versus baseline at both doses, so the rise was already present at the first check. That says when a blood level moved, which is a different thing from when a person would notice anything.

Question 5

Did a higher amount of glutathione do more?

Accepted Answer

Only one human trial compared two amounts directly, and it measured accumulated body stores rather than any clinical benefit. That trial administered 250 mg or 1,000 mg daily, and circulating levels rose with both. The biggest changes that trial reports belong to the larger amount: at 6 months, mean GSH levels increased 30-35 % in erythrocytes, plasma and lymphocytes, which are red cells, the fluid part of blood and white cells, in the high-dose group. That is a dose response for a laboratory measurement, and the evidence stops there. Nothing in that trial demonstrates that the larger increase in stores produced a larger effect on skin, blood sugar or any outcome a person would notice. The reviews treat this as an open problem. A 2026 review of glutathione in type 2 diabetes lists dose-response mapping, and long-term outcomes among the gaps that are urgently needed to move the field forward, and a 2026 review of oral use asks for research to determine the best dosages. Both reviews describe an optimal amount and an upper limit that remain undetermined.

Question 6

What amounts are used for skin lightening, by mouth or by drip?

Accepted Answer

No agreed amount exists for either, and the main review on the subject says so as its central finding. The 2025 skin-lightening review found that oral administration shows significant but variable decreases in melanin levels, melanin being the pigment that darkens skin, without giving an amount that produced them. The intravenous route has the same gap with higher stakes. The review describes the drip as further aggravated by a lack of standardized dosing protocols, which means two clinics can give very different quantities for the same cosmetic aim. Its call is for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. For a reader trying to judge a skin-lightening course, that leaves a specific gap. The oral amounts on this page come from trials of blood levels, diabetes, acne and arteries, not from a skin-lightening trial with a stated dose, and the drip has no published amount at all among these sources. What is known about harm from the drip is laid out on the Glutathione safety page.

Question 7

Is there a cycle or a break in the published glutathione work?

Accepted Answer

No trial among the research behind this page used a cycle, a planned break or an on-off pattern. Every schedule was continuous daily intake for a fixed period, followed by measurement. That matters for a common question about whether stores stay up after stopping. The six-month body-stores trial measured levels while people were still taking it, and its authors conclude that daily consumption of GSH supplements was effective at increasing body compartment stores of GSH. Daily consumption is the operative phrase, since the abstract reports no measurement after the capsules stopped. The same applies to the diabetes trial, which reports changes within the six months of supplementation, and to the children's trial, which ran 24 weeks and stopped. So whether levels fall back in days or months, and whether a break changes anything, has not been asked among these sources. Any cycling schedule seen online is an invention layered on top of trials that never tested one, rather than a finding drawn from them.

Question 8

Did any glutathione trial start low and build up?

Accepted Answer

No. Every human trial behind this page administered its full amount from the first day and maintained it throughout, so there is no published starting dose and no titration schedule to report. Titration means increasing an amount step by step to find a tolerated level. That was a reasonable design for what the trials were asking. The diabetes trial was testing whether 500 mg a day on top of standard care would move blood markers, and it found that blood GSH increased (Cohen's d = 1.01) and 8-OHdG decreased (Cohen's d = −1.07) significantly within three months, 8-OHdG being a marker of damage to DNA. Cohen's d is a standard measure of how large an effect is. It also means the trials say nothing about whether a lower opening amount changes anything. The stomach complaints that two 2026 reviews describe as the most commonly reported problem were reported under fixed amounts, and no study among these sources tested whether building up slowly reduces them. That does not tell you a gradual start is pointless; it tells you the comparison was never part of any trial design.

Question 9

Does a liposomal form change how much glutathione is needed?

Accepted Answer

That is the claim behind liposomal products, and no human amount has been published for one among the research behind this page. The liposomal evidence is animal work without a dose in its abstract. In mice with tuberculosis spread to the liver and spleen, liposomal glutathione raised tissue levels, and M. tb survival was significantly reduced in the liver and spleen following L-GSH supplementation, M. tb being the tuberculosis bacterium. A 2020 review argued for the possible use of liposomal GSH as an adjunctive treatment in COVID-19, without testing any amount in a person. The idea that a liposome lets a smaller amount do the same work is plausible, which is not the same as measured. The 2026 diabetes review lists exploring targeted delivery systems among its future directions, which is a way of saying the comparison has not been run. A liposomal label quoting a smaller figure as equivalent to a larger plain one is making a claim the published trials have not tested.

Question 10

Do the animal glutathione amounts transfer to people?

Accepted Answer

No, and we do not convert them. The animal studies express amounts in units that have no human counterpart, which is reason enough to leave them where they are. Chinese mitten crabs received glutathione as a share of their food, at 0, 300, 600, 900, and 1200 mg/kg diet weight, which is milligrams per kilogram of feed rather than of body weight. In a rat heart study, the animals were given the glutathione precursor N-acetylcysteine (NAC, 100 mg IP per animal), injected into the abdomen, and in those rat hearts NAC treatment increased cardiac glutathione content by 42%. A precursor is a raw material the body uses to make glutathione, so that figure is not a glutathione dose at all. Each of those numbers belongs to its species, its route and its question. Scaling from a crab's diet or a rat's abdomen to a person's capsule is not validated, and a figure that looks precise in an animal study becomes guesswork the moment it is carried across.

Question 11

Why is a glutathione study amount not a protocol?

Accepted Answer

Because each amount was chosen to answer a research question, in a particular group, for a fixed period, and none of the trials was designed to find the right amount for anyone. A protocol would need that comparison, and the reviews agree it has not been made. The 2026 review of glutathione in HIV and tuberculosis describes the shortfall plainly: translation into routine clinical practice remains limited by methodological heterogeneity, short study durations, and lack of standardized biomarkers and long-term outcome data. Heterogeneity here means the trials were built differently from one another, so their amounts cannot simply be lined up and averaged. There is also no regulator's figure to anchor against. Every human trial behind this page tested glutathione as supplementation rather than as an approved medicine, so no label exists that sets an amount for any indication. The amounts above describe what was given. What a reader decides to do with them is outside what these studies can answer, and the broader evidence on what glutathione does is on the Glutathione overview.

Trial	Daily amount by mouth	Length
Body-stores trial	250 or 1,000 mg	6 months
Trial in obese men	1000 mg	3 weeks
Diabetes trial (125 patients)	500 mg, on top of usual medicines	Six months
Acne trial	500 mg	4 weeks
Vascular trial	200 mg, with 2 g of citrulline	Not stated in this section

Glutathione protocols in the published literature